Therefore, in this work, we aimed to characterize the role of RIPK1 in tumor progression and the tumor immune microenvironment (TIME) of DGs through comprehensive in silico analyses of patient databases, as well as pre-clinical in vitro assays evaluating the effect of combining a commercial RIPK1 inhibitor with a chemotherapeutic agent on cell proliferation and apoptosis. Here, RIPK1 is linked to neoplasm.